Nautilus Biotechnology Launches “First Access Challenge”
17 November 2022 - 12:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced the launch of the First
Access Challenge, a research competition for high-impact work in
single-molecule proteomics. Scientists of all backgrounds are
invited to submit proposals and gain early access to Nautilus’
Proteome Analysis Platform.
“We are excited to launch the First Access
Challenge with the goal of enabling researchers from a broad
spectrum of disciplines to uncover new biological insights and
explore new areas of the proteome at massive scale,” said Nautilus
co-founder and Chief Scientist Parag Mallick.
Nautilus’ single-molecule, large-scale platform
uses Protein Identification by Short-epitope Mapping (PrISM) with
an aim of easily and sensitively measuring billions of intact
proteins. Applications for the Challenge are welcomed across many
fields, including oncology, neuroscience, cardiology, and
immunology.
Details of the First Access
Challenge
Three winning proposals will be selected in 2023 to
receive a quantitative, single-molecule analysis of 12 samples in
collaboration with Nautilus’ scientists, as well as a conference
travel award to present the data and writing assistance for a
peer-reviewed journal submission.
Scientists are invited to submit their abstracts
through Nautilus’ website before the deadline of Friday, February
10, 2023. Submissions will be evaluated by the Nautilus team for
their potential scientific impact, and the three winning proposals
will be announced at the US HUPO 2023 Conference, which will be
held in Chicago, IL on March 4-8, 2023.
For more detailed information, please see the FAQ
section of the contest submission page.
About Nautilus Biotechnology,
Inc.With its corporate headquarters in Seattle and its
research and development headquarters in the San Francisco Bay
Area, Nautilus is a development stage life sciences company
creating a protein analysis platform for quantifying and unlocking
the complexity of the proteome. Nautilus’ mission is to transform
the field of proteomics by democratizing access to the proteome and
enabling fundamental advancements across human health and medicine.
To learn more about Nautilus, visit www.nautilus.bio.
Media
Contactpress@nautilus.bio
Special Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of federal securities laws.
Forward-looking statements in this press release include, but are
not limited to, statements regarding Nautilus’ expectations
regarding the company’s business operations, expectations with
respect to the functionality and performance of Nautilus’ Proteome
Analysis Platform, its potential to easily and sensitively measure
billions of intact single molecule proteins, and its ability to
enable scientific explorations and discovery. These statements are
based on numerous assumptions concerning the development of
Nautilus’ products, target markets, and other current and emerging
proteomics technologies, and involve substantial risks,
uncertainties and other factors that may cause actual results to be
materially different from the information expressed or implied by
these forward-looking statements. Risks and uncertainties that
could materially affect the accuracy of Nautilus’ assumptions and
its ability to achieve the forward-looking statements set forth in
this press release include (without limitation) the following:
Nautilus’ product platform is not yet commercially available and
remains subject to significant scientific and technical
development, which is inherently challenging and difficult to
predict, particularly with respect to highly novel and complex
products such as those being developed by Nautilus. Even if our
development efforts are successful, our product platform will
require substantial validation of its functionality and utility in
life science research. In the course of Nautilus’ scientific and
technical development and associated product validation and
commercialization, we may experience material delays as a result of
unanticipated events. We cannot provide any guarantee or assurance
with respect to the outcome of our development, collaboration, and
commercialization initiatives or with respect to their associated
timelines. For a more detailed description of additional risks and
uncertainties facing Nautilus and its development efforts,
investors should refer to the information under the caption “Risk
Factors” in our Annual Report on Form 10-K as well as in our
Quarterly Report on Form 10-Q filed for the quarter ended September
30, 2022 and our other filings with the SEC. The forward-looking
statements in this press release are as of the date of this press
release. Except as otherwise required by applicable law, Nautilus
disclaims any duty to update any forward-looking statements. You
should, therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this press release.
Disclosure Information
Nautilus uses filings with the Securities and
Exchange Commission, its website (www.nautilus.bio), press
releases, public conference calls, public webcasts, and its social
media accounts as means of disclosing material non-public
information and for complying with Regulation FD. Therefore,
Nautilus encourages investors, the media, and others interested in
Nautilus to review the information it makes public in these
locations, as such information could be deemed to be material
information.
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Apr 2024 to May 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From May 2023 to May 2024